Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases.

Ann Surg Oncol 2011 Apr 3;18(4):1081-7. Epub 2010 Nov 3.

Department of Radiation Oncology, University of Texas Southwestern, 5801 Forest Park Road, Dallas, TX, USA.

Purpose: To identify a tolerable and effective dose for 5-fraction stereotactic body radiotherapy for hepatic metastases.

Methods: Patients were enrolled onto three dose-escalation cohorts: 30 Gy in 3 fractions, 50 Gy in 5 fractions, and 60 Gy in 5 fractions. Eligible patients had one to five hepatic metastases, ability to spare a critical hepatic volume (volume receiving <21 Gy) of 700 ml, adequate baseline hepatic function, no concurrent antineoplastic therapy, and a Karnofsky performance score of ≥60. Dose-limiting toxicity included treatment-related grade 3 toxicity in the gastrointestinal, hepatobiliary/pancreas, and metabolic/laboratory categories. Any grade 4 or 5 event attributable to therapy was defined as a dose-limiting toxicity. Local control (LC) and complete plus partial response rates were assessed.

Results: Twenty-seven patients, 9 in each cohort, with 37 lesions were enrolled and treated: 17 men and 11 women; median age 62 (range 48-86) years; most common site of primary disease, colorectal (44.4%). Median follow-up was 20 (range 4-53) months. There was no grade 4 or 5 toxicity or treatment-related grade 3 toxicity. Actuarial 24-month LC rates for the 30-, 50-, and 60-Gy cohorts were 56%, 89%, and 100%, respectively. There was a statistically significant difference for LC between the 60- and 30-Gy cohorts (P = 0.009) but not between the 60- and 50-Gy cohorts (P = 0.56) or the 50- and 30-Gy cohorts (P = 0.091). The maximum tolerated dose was not reached.

Conclusions: A dose of 60 Gy in 5 fractions can be safely delivered to selected patients with hepatic metastases as long as the critical liver volume is respected. A dose of 60 Gy in 5 fractions yields an excellent level of LC.

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-010-1405-5DOI Listing
April 2011
6 Reads

Publication Analysis

Top Keywords

body radiotherapy
8
hepatic metastases
8
stereotactic body
8
patients hepatic
8
dose-escalation cohorts
4
cohorts 30 gy
4
30 gy fractions
4
fractions 50 gy
4
three dose-escalation
4
enrolled three
4
5-fraction stereotactic
4
radiotherapy hepatic
4
hepatic metastasesmethods
4
patients enrolled
4
50 gy fractions
4
volume receiving
4
metastases ability
4
hepatic volume
4
ability spare
4
spare critical
4

References

(Supplied by CrossRef)

EK Abdalla et al.
Ann Surg 2004

Y Fong et al.
CA Cancer J Clin 1995

Y Fong et al.
Ann Surg 1999

J Scheele et al.
World J Surg 1995

MA Choti et al.
Ann Surg 2002

TM Pawlik et al.
J Gastrointest Surg 2007

TM Pawlik et al.
Ann Surg 2005

T Baere de et al.
AJR Am J Roentgenol 2000

M Giovannini et al.
Cancer 1994

DJ Kerr et al.
Lancet 2003

T Shibata et al.
Cancer 2000

Similar Publications